@article{986d82b8eea240118fe81f540a034d7e,
title = "5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis",
abstract = "Ulcerative colitis (UC) is one of the major clinical phenotypes of inflammatory bowel diseases. Although 5-aminosalicylic acid (5-ASA) is widely used for UC and its efficacy and safety have been demonstrated, a few patients paradoxically develop a severe exacerbation of colitis by 5-ASA administration. It is crucial to know clinical features including endoscopic findings in this condition for making a correct diagnosis and a prompt decision to withdraw the medication. Here, we report case series with UC exacerbated by 5-ASA. Medical records of 8 UC patients experiencing an exacerbation of colitis after induction of 5-ASA that was improved by the withdrawal of 5-ASA but also re-aggravated by dose increase or re-administration of 5-ASA were reviewed. The patients were newly diagnosed with UC, started 5-ASA and developed an exacerbation in approximately 2 to 3 weeks. They did not appear to have systemic allergic reactions. Seven of the 8 patients had a high fever. Three of 5 patients who undertook total colonoscopy showed right-side-dominant colitis. These findings suggest clinical characteristics in this condition. Further assessment of clinical and endoscopic features in more cases is necessary for establishing diagnostic criteria and understanding underlying mechanisms in those cases where 5-ASA aggravates the colitis.",
keywords = "5-Aminosalicylic acid, Clinical features, Colitis, Endoscopic findings, Exacerbation, Ulcerative",
author = "Jun Miyoshi and Katsuyoshi Matsuoka and Atsushi Yoshida and Makoto Naganuma and Tadakazu Hisamatsu and Tomoharu Yajima and Nagamu Inoue and Susumu Okamoto and Yasushi Iwao and Haruhiko Ogata and Fumiaki Ueno and Toshifumi Hibi and Takanori Kanai",
note = "Funding Information: Katsuyoshi Matsuoka received lecture fees from Mitsubishi Tanabe Pharma Co., AbbVie GK, Janssen Pharmaceutical K.K., and Takeda Pharmaceutical Co. Ltd. Tadakazu Hisa-matsu received research grants from Mitsubishi Tanabe Pharma Co., EA pharma Co. Ltd., AbbVie GK, JIMRO Co. Ltd., Asahi Kasei Kuraray Medical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., and Mochida Pharmaceutical Co. Ltd., serves as a consultant to EA pharma Co. Ltd., AbbVie GK, Celgene K.K., Janssen Pharmaceutical K.K., Pfizer Inc., Nichi-Iko Pharmaceutical Co. Ltd., and received lecture fees from Mitsubishi Tanabe Pharma Co., Abbvie GK, EA pharma Co. Ltd., Kyorin Pharmaceutical Co. Ltd., and JIMRO Co. Toshifumi Hibi received lecture fees from Mitsubishi Tanabe Pharma Co. Takanori Kanai received research grants from Miyarisan Pharmaceutical Co., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Ezaki Glico Co. Ltd., and Otsuka Pharmaceutical Co. Ltd. and lecture fees from Mitsubishi Tanabe Pharma Co., AstraZen-eca K.K., Miyarisan Pharmaceutical Co., and Zeria Pharmaceutical Co. Ltd. Publisher Copyright: {\textcopyright} 2018. Korean Association for the Study of Intestinal Diseases.",
year = "2018",
month = oct,
day = "1",
doi = "10.5217/ir.2018.00015",
language = "English",
volume = "16",
pages = "635--640",
journal = "Intestinal Research",
issn = "1598-9100",
publisher = "Korean Association for the Study of Intestinal Diseases",
number = "4",
}